The interchangeability of original tumor necrosis factor- α inhibitors and biosimilars in rheumatology: experience in replacing original infliximab with Flammagis for ankylosing spondylitis

The interchangeability of original tumor necrosis factor- α inhibitors and biosimilars in rheumatology: experience in replacing original infliximab with Flammagis for ankylosing spondylitis

The paper discusses prospects for prescribing tumor necrosis factor-α (TNF-α) inhibitor biosimilars, their interchangeability with original drugs for inflammatory joint diseases. It describes clinical cases when original infliximab is replaced with its biosimilar Flammagis for ankylosing spondylitis...

Full description

Bibliographic Details
Main Authors: Yu. V. Muravyev, V. V. Lebedeva, A. S. Starkova, D. G. Rumyantseva, M. M. Urumova, Sh. Erdes
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2020-05-01
Series:Современная ревматология
Subjects:
tumor necrosis factor-α inhibitors
biosimilars
rheumatoid arthritis
psoriatic arthritis
ankylosing spondylitis
flammagis
Online Access:https://mrj.ima-press.net/mrj/article/view/1027

Internet

https://mrj.ima-press.net/mrj/article/view/1027

Similar Items